Downloaded 516 times
![Regulatory Agencies for Toxicity Studies:
For regulatory purposes, and derived from their scientific objectives, non-clinical studies are divided
into three parts:
Investigations of the pharmacodynamics actions of a compound (primary and secondary
pharmacodynamics and safety pharmacology);
Investigations of the compound’s behaviour and fate in the organism (pharmacokinetics;
absorption, distribution, metabolism, excretion [ADME]); and
Investigations to ensure that the substance does not pose any potential untoward safety risk
(toxicology) when it may finally be administered to humans.](https://image.slidesharecdn.com/saini-150509073505-lva1-app6892/75/International-Guidelines-and-Regulatory-Agencies-for-Toxicity-Studies-4-2048.jpg)
Uploaded bySuneal Saini
International Guidelines and Regulatory Agencies for Toxicity Studies
This document discusses international guidelines and regulatory agencies for toxicity studies. It outlines regulatory agencies like the ICH, OECD, FDA, and WHO that provide guidelines for non-clinical safety testing. The ICH and WHO have produced comprehensive guidelines to assess risks like carcinogenicity, genotoxicity, and reproductive toxicity. The OECD also provides numerous guidelines for specific toxicity study types. The FDA provides guidance documents and draft guidances related to studies like carcinogenicity, immunotoxicology, and photosafety testing.
More Related Content
Similar to International Guidelines and Regulatory Agencies for Toxicity Studies
International Guidelines and Regulatory Agencies for Toxicity Studies
- 1. International Guidelines andRegulatory Agencies for Toxicity Studies Supervised by: Dr. Ajay Gaur H.O.D. Quality Assurance Submitted by: Sunil Saini M.Pharm (P`ceutics) Sem-2nd LACHOO MEMORIAL COLLEGE OF SCIENCE AND TECHNOLOGY (PHARMACY WING) JODHPUR JAI NARAYAN VYAS UNIVERSITY, JODHPUR
- 2. Contents: Introduction RegulatoryAgencies for Toxicity Studies International Guidelines ICH/WHO OECD FDA
- 3. Introduction: One ofthe most important milestones in product development is the decision to enter into clinical trials with a candidate product. This important decision is based, in part, on data produced during non-clinical safety testing of the candidate during the preclinical phases of development. The quality and reproducibility of safety data are hereby key components of their utility for supporting the assumption of safety in humans.
- 4. Regulatory Agencies forToxicity Studies: For regulatory purposes, and derived from their scientific objectives, non-clinical studies are divided into three parts: Investigations of the pharmacodynamics actions of a compound (primary and secondary pharmacodynamics and safety pharmacology); Investigations of the compound’s behaviour and fate in the organism (pharmacokinetics; absorption, distribution, metabolism, excretion [ADME]); and Investigations to ensure that the substance does not pose any potential untoward safety risk (toxicology) when it may finally be administered to humans.
- 5. Cont…. Regulatory Agencies: ICH OECD FDA WHO
- 6. International Guidelines: ICH& WHO: International Conference on Harmonisation & World Health Organization ICH & WHO has produced a comprehensive set of safety Guidelines to uncover potential risks like carcinogenicity, genotoxicity and reprotoxicity. A recent breakthrough has been a non-clinical testing strategy for assessing the QT interval prolongation liability(most important reason now a days to withdraw drug from market). CARCINOGENICITY STUDIES S1A: Need for Carcinogenicity Studies of Pharmaceuticals This document provides a consistent definition of the circumstances under which it is necessary to undertake carcinogenicity studies on new drugs. These recommendations take into account the known risk factors as well as the intended indications and duration of exposure.
- 7. Cont…. S1B: Testingfor Carcinogenicity of Pharmaceuticals This document provides guidance on the need to carry out carcinogenicity studies in both mice and rats. S1C(R2): Dose Selection for Carcinogenicity Studies of Pharmaceuticals This document addresses the criteria for the selection of the high dose to be used in carcinogenicity studies on new therapeutic agents to harmonize current practices and improve the design of studies.
- 8. Cont…. GENOTOXICITY STUDIES S2(R1):Guidance on Genotoxicity Testing and Data Interpretation for Pharmaceuticals Intended for Human Use S2A, S2B S2A: Guidance on Specific Aspects of Regulatory Genotoxicity Tests for Pharmaceuticals This document provided specific guidance and recommendations for in vitro and in vivo tests and on the evaluation of test results. S2B: Genotoxicity: A Standard Battery for Genotoxicity Testing for Pharmaceuticals This document addressed two fundamental areas of genotoxicity testing: the identification of a standard set of assays to be conducted for registration, and the extent of confirmatory experimentation in any particular genotoxicity assay in the standard battery.
- 9. Cont…. TOXICOKINETICS AND PHARMACOKINETICS S3A: Note for Guidance on Toxicokinetics: The Assessment of Systemic Exposure in Toxicity Studies This document gives guidance on developing test strategies in toxicokinetics and the need to integrate pharmacokinetics into toxicity testing. S3B: Pharmacokinetics: Guidance for Repeated Dose Tissue Distribution Studies This document gives guidance on circumstances when repeated dose tissue distribution studies should be considered (i.e., when appropriate data cannot be derived from other sources).
- 10. Cont…. TOXICITY TESTING S4:Duration of Chronic Toxicity Testing in Animals (Rodent and Non Rodent Toxicity Testing) The text incorporates the guidance for repeat-dose toxicity tests that was agreed at the time of ICH 1, in 1991 (reduction of the duration of repeat dose toxicity studies in the rat from 12 to 6 months).
- 11. Cont…. REPRODUCTIVE TOXICOLOGY S5(R2):Detection of Toxicity to Reproduction for Medicinal Products & Toxicity to Male Fertility S5A,S5B(M) This document provides guidance on tests for reproductive toxicity. It defines the periods of treatment to be used in animals to better reflect human exposure to medical products and allow more specific identification of stages at risk.
- 12. Cont…. BIOTECHNOLOGICAL PRODUCTS S6(R1):Preclinical Safety Evaluation of Biotechnology-Derived Pharmaceuticals This document covers the pre-clinical safety testing requirements for biotechnological products.
- 13. Cont…. PHARMACOLOGY STUDIES S7A:Safety Pharmacology Studies for Human Pharmaceuticals This document addresses the definition, objectives and scope of safety pharmacology studies. S7B: The Non-Clinical Evaluation of the Potential for Delayed Ventricular Repolarization (QT Interval Prolongation) by Human This Guideline describes a non-clinical testing strategy for assessing the potential of a test substance to delay ventricular repolarization.
- 14. Cont…. IMMUNOTOXICOLOGY STUDIES S8:Immunotoxicity Studies for Human This Guideline addresses the recommendations on nonclinical testing for immunosuppression induced by low molecular weight drugs (non-biologicals).
- 15. Cont…. NONCLINICAL EVALUATION FORANTICANCER PHARMACEUTICALS S9: Nonclinical Evaluation for Anticancer This Guideline provides information for pharmaceuticals that are only intended to treat cancer in patients with late stage or advanced disease regardless of the route of administration, including both small molecule and biotechnology-derived pharmaceuticals. PHOTOSAFETY EVALUATION S10: Photosafety Evaluation of Pharmaceuticals (Draft Document) The S10 draft Guideline has been released for consultation under Step 2 of the ICH process in November 2012.
- 16. OECD OECD: Organisationfor Economic Co-operation and Development The mission of the OECD is to promote policies that will improve the economic and social well- being of people around the world. The OECD provides a forum in which governments can work together to share experiences and seek solutions to common problems. GUIDELINES: 402 Acute Dermal Toxicity 403 Acute Inhalation Toxicity 404 Acute Dermal Irritation/Corrosion 405 Acute Eye Irritation/Corrosion
- 17. Cont…. 406 SkinSensitisation 407 Repeated Dose 28-day Oral Toxicity Study in Rodents 408 Repeated Dose 90-Day Oral Toxicity Study in Rodents 409 Repeated Dose 90-Day Oral Toxicity Study in Non-Rodents 410 Repeated Dose Dermal Toxicity: 21/28-day Study 411 Subchronic Dermal Toxicity: 90-day Study 412 Repeated Dose Inhalation Toxicity: 28-day or 14-day Study 413 Subchronic Inhalation Toxicity: 90-day Study 414 Prenatal Developmental Toxicity Study 415 One-Generation Reproduction Toxicity Study
- 18. Cont…. 416 Two-GenerationReproduction Toxicity Study 417 Toxicokinetics 420 Acute Oral Toxicity - Fixed Dose Method 421 Reproduction/Developmental Toxicity Screening Test 422 Combined Repeated Dose Toxicity Study with the Reproduction 423 Acute Oral toxicity - Acute Toxic Class Method 424 Neurotoxicity Study in Rodents 425 Acute Oral Toxicity: Up-and-Down Procedure 451 Carcinogenicity Studies 452 Chronic Toxicity Studies 453 Combined Chronic Toxicity/Carcinogenicity Studies
- 19. Cont…. 471 BacterialReverse Mutation Test 473 In vitro Mammalian Chromosomal Aberration Test 474 Mammalian Erythrocyte Micronucleus Test 475 Mammalian Bone Marrow Chromosomal Aberration Test 476 In vitro Mammalian Cell Gene Mutation Test 477 Genetic Toxicology: Sex-Linked Recessive Lethal Test in Drosophila melanogaster 478 Genetic Toxicology: Rodent Dominant Lethal Test 479 Genetic Toxicology: In vitro Sister Chromatid Exchange Assay in Mammalian Cells 480 Genetic Toxicology: Saccharomyces cerevisiae, Gene Mutation Assay 481 Genetic Toxicology: Saccharomyces cerevisiae, Mitotic Recombination Assay 482 Genetic Toxicology: DNA Damage and Repair, Unscheduled DNA Synthesis in Mammalian Cells in vitro
- 20. Cont…. 483 MammalianSpermatogonial Chromosome Aberration Test 484 Genetic Toxicology: Mouse Spot Test 485 Genetic Toxicology: Mouse Heritable Translocation Assay 486 Unscheduled DNA Synthesis (UDS) Test with Mammalian Liver Cells in vivo
- 21. Cont…. DRAFT GUIDELINES 403Acute Inhalation Toxicity 404 Acute Dermal Irritation/Corrosion 405 Acute Eye Irritation/Corrosion 426 Developmental Neurotoxicity Study 429 Skin Sensitisation: Local Lymph Node Assay 430 In Vitro Skin Corrosion: Transcutaneous Electrical Resistance Test (TER) 431 In Vitro Skin Corrosion: Human Skin Model Test 432 In Vitro 3T3 NRU Phototoxicity Test
- 22. FDA FDA: Foodand Drug Administration FDA is responsible for protecting the public health by assuring the safety, efficacy and security of human and veterinary drugs, biological products, medical devices, our nation’s food supply, cosmetics, and products that emit radiation. FDA is also responsible for advancing the public health by helping to speed innovations that make medicines more effective, safer, and more affordable and by helping the public get the accurate, science-based information they need to use medicines and foods to maintain and improve their health. FDA also has responsibility for regulating the manufacturing, marketing and distribution of tobacco products to protect the public health and to reduce tobacco use by minors.
- 23. Cont…. Guidance Documents: Content and Format of INDs(Investigational New Drugs) for Phase 1 Studies Single Dose Acute Toxicity Testing for Pharmaceuticals Product Specific guidance anti-virals vaginal contraceptives and STD preventatives Special Protocol Assessment Submission in Electronic Format
- 24. Cont…. Draft Guidances: Carcinogenicity study protocols Immunotoxicology Photosafety testing Statistical evaluation of carcinogenicity studies
- 25. Cont…. Types of ToxicologyStudies Recommended General Toxicology acute and repeat dose toxicology studies Special Toxicology Studies local irritation studies, e.g., site specific, ocular hypersensitivity studies for inhalation and dermal drug products Reproductive and Developmental Toxicology Studies male and female fertility embryonic and fetal development post-natal reproductive and developmental effects
- 26.